In the news release, The Galien Foundation Announces 2026 Prix Galien UK Award Candidates for "Best Biotechnology Product," "Best Digital Health Solution," "Best Medical...
Available now in public preview on Zilliz Cloud, Vector Lakebase keeps production vector search at its core and adds shared lake-native storage and on-demand...
SEATTLE, June 10, 2026 /PRNewswire/ -- RVL Strength, a Seattle-based fitness equipment company, today officially launches its flagship product, RVL Wings. This single and...
HighlightsExploration Permit Applications filed for:Phase 2 Diamond Drilling at the Pt. Leamington VMS Deposit targeting deposit resource upgrade / expansion of the emerging Kraken...
HighlightsExploration Permit Applications filed for:Phase 2 Diamond Drilling at the Pt. Leamington VMS Deposit targeting deposit resource upgrade / expansion of the emerging Kraken...
Industry-academia collaboration brings hands-on AI learning and real-world technology exposure to students across three campusesCOIMBATORE, India, June 4, 2026 /PRNewswire/ -- Orion Innovation ("Orion"), a...
Identity-First Reachability™ eliminates the attack surface that AI agents, MCP servers, and LLMs create — addressing the #1 breach vector in enterprise security todayCHARLOTTE,...
MEQUON, Wis., June 2, 2026 /PRNewswire/ -- Vector Science & Therapeutics (TSXV: PAIN) ("Vector" or the "Company") today announced that the Board of Directors...
EMERYVILLE, Calif., Aug. 15, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on August 12, 2025, the compensation committee of the Company’s board of directors granted three new non-executive employees 58,900 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, which was approved by the Company’s board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
PAPZIMEOS approval marks a historic milestone for the RRP patient community as the first and only FDA-approved therapy for the treatment of adults with...